Home / Market News / $PALI
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Palisade Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 11, 2026, 2:11 PM UTC · Primary ticker $PALI

Palisade Bio reported its Q3 2026 financial results and provided an update on its lead drug candidate, PALI-2108. The company is progressing its Phase 2 clinical trials for inflammatory bowel disease (IBD), with enrollment ongoing for ulcerative colitis and preparation for a Crohn's disease study, indicating continued R&D progress which could be moderately positive for the stock.

Palisade Bio announced its third-quarter 2026 financial results and provided a business update focused on its lead product candidate, PALI-2108. The key development is the ongoing Phase 2 ASCENTRA-UC study for ulcerative colitis, with topline results expected in Q4 2027, and the impending start of the Phase 2a ASCENTRA-CD study for Crohn's disease following FDA IND clearance. This news indicates continued progress in the company's drug development pipeline, which is crucial for a clinical-stage biotech. For traders, this represents a moderate positive as it de-risks the development timeline slightly and provides future catalysts (trial results). The short-term implication is a potential modest positive reaction due to operational progress, while the long-term implication hinges on the success of these clinical trials. The key opportunity is for investors who believe in the potential of PALI-2108, as successful trial outcomes could significantly boost the stock.

$PALI positive Advancing lead drug candidate in clinical trials
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.